{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:55:40Z","timestamp":1793404540414,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"none"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>For secondary prevention of coronary artery disease (CAD) antiplatelet therapy is essential. For patients undergoing a\u00a0percutaneous coronary intervention (PCI) temporary dual antiplatelet platelet therapy (DAPT: aspirin combined with a\u00a0P2Y12 blocker) is mandatory, but leads to more bleeding than single antiplatelet therapy with aspirin. Therefore, to reduce bleeding after a\u00a0PCI the duration of DAPT is usually kept as short as clinically acceptable; thereafter aspirin monotherapy is administered. Another option to reduce bleeding is to discontinue aspirin at the time of DAPT cessation and thereafter to administer P2Y12 blocker monotherapy. To date, five randomised trials have been published comparing DAPT with P2Y12 blocker monotherapy in 32,181 stented patients. Also two meta-analyses addressing this novel therapy have been presented. P2Y12 blocker monotherapy showed a\u00a050\u201360% reduction in major bleeding when compared to DAPT without a\u00a0significant increase in ischaemic outcomes, including stent thrombosis. This survey reviews the findings in the current literature concerning P2Y12 blocker monotherapy after PCI.<\/jats:p>","DOI":"10.1007\/s12471-021-01582-7","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T09:06:29Z","timestamp":1623143189000},"page":"566-576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["P2Y12 blocker monotherapy after percutaneous coronary intervention"],"prefix":"10.1007","volume":"29","author":[{"given":"F. W. A.","family":"Verheugt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Damman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A. J.","family":"Damen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Wykrzykowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. C. I.","family":"Woelders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. -J. M.","family":"van Geuns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"key":"1582_CR1","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti\u00a0J, Wijns\u00a0W, Saraste\u00a0A, et\u00a0al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart\u00a0J. 2020;41:407\u201377.","journal-title":"Eur Heart J"},{"key":"1582_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann\u00a0FJ, Sousa-Uva\u00a0M, Ahlsson\u00a0A, et al. 2018 ESC\/EACTS guidelines on myocardial revascularization. Eur Heart\u00a0J. 2019;40:87\u2013165.","journal-title":"Eur Heart J"},{"key":"1582_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa575","author":"JP Collet","year":"2020","unstructured":"Collet\u00a0JP, Thiele\u00a0H, Barbato\u00a0E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart\u00a0J. 2020; https:\/\/doi.org\/10.1093\/eurheartj\/ehaa575.","journal-title":"Eur Heart J"},{"key":"1582_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez\u00a0B, James\u00a0S, Agewall\u00a0S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart\u00a0J. 2018;39:119\u201377.","journal-title":"Eur Heart J"},{"key":"1582_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jacc.2019.02.080","volume":"74","author":"FWA Verheugt","year":"2019","unstructured":"Verheugt\u00a0FWA, Ten Berg\u00a0JM, Storey\u00a0RF, Cuisset\u00a0T, Granger\u00a0CB. Antithrombotics: from aspirin to DOACs in coronary artery disease and atrial fibrillation. J\u00a0Am Coll Cardiol. 2019;74:699\u2013711.","journal-title":"J Am Coll Cardiol"},{"key":"1582_CR6","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1161\/01.CIR.72.6.1177","volume":"72","author":"C Patrono","year":"1985","unstructured":"Patrono\u00a0C, Ciabattoni\u00a0G, Patrignani\u00a0P, et\u00a0al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985;72:1177\u201384.","journal-title":"Circulation"},{"key":"1582_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12265-013-9524-6","volume":"7","author":"MR Thomas","year":"2014","unstructured":"Thomas\u00a0MR, Storey\u00a0RF. Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes. J\u00a0Cardiovasc Transl Res. 2014;7:19\u201328.","journal-title":"J Cardiovasc Transl Res"},{"key":"1582_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/B978-0-12-386930-2.00006-9","volume":"124","author":"MR Thomas","year":"2014","unstructured":"Thomas\u00a0MR, Storey\u00a0RF. Genetics of response to antiplatelet therapy. Prog Mol Biol Transl Sci. 2014;124:123\u201353.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"1582_CR9","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.2174\/138161212803251989","volume":"18","author":"S Ahmad","year":"2012","unstructured":"Ahmad\u00a0S, Storey\u00a0RF. Development and clinical use of prasugrel and ticagrelor. Curr Pharm Des. 2012;18:5240\u201360.","journal-title":"Curr Pharm Des"},{"key":"1582_CR10","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","volume":"120","author":"PA Gurbel","year":"2009","unstructured":"Gurbel\u00a0PA, Bliden\u00a0KP, Butler\u00a0K, et al. Randomized double-blind assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study. Circulation. 2009;120:2577\u201385.","journal-title":"Circulation"},{"key":"1582_CR11","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1111\/j.1538-7836.2011.04419.x","volume":"9","author":"RF Storey","year":"2011","unstructured":"Storey\u00a0RF, Bliden\u00a0KP, Ecob\u00a0R, et\u00a0al. Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared to clopidogrel in patients with high antiplatelet responses. J\u00a0Thromb Haemost. 2011;9:1730\u20137.","journal-title":"J Thromb Haemost"},{"key":"1582_CR12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/MCA.0000000000000541","volume":"28","author":"H Zhang","year":"2017","unstructured":"Zhang\u00a0H, Zhang\u00a0P, Dong\u00a0P, et al. Effect of ticagrelor versus prasugrel on platelet reactivity: a\u00a0meta-analysis. Coron Artery Dis. 2017;28:597\u2013604.","journal-title":"Coron Artery Dis"},{"key":"1582_CR13","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jacc.2015.12.062","volume":"67","author":"RF Storey","year":"2016","unstructured":"Storey\u00a0RF, Angiolillo\u00a0DJ, Bonaca\u00a0MP, et al. Platelet inhibition with ticagrelor 60\u202fmg versus 90\u202fmg twice daily in the PEGASUS-TIMI 54 trial. J\u00a0Am Coll Cardiol. 2016;67:1145\u201354.","journal-title":"J Am Coll Cardiol"},{"key":"1582_CR14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1177\/2048872614554108","volume":"4","author":"G Parodi","year":"2015","unstructured":"Parodi\u00a0G, Storey\u00a0RF. Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. Eur Heart J Acute Cardiovasc Care. 2015;4:555\u201360.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"1582_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1161\/01.CIR.82.1.17","volume":"82","author":"F Balsano","year":"1990","unstructured":"Balsano\u00a0F, Rizzon\u00a0P, Violi\u00a0F, et\u00a0al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. Circulation. 1990;82:17\u201326.","journal-title":"Circulation"},{"key":"1582_CR16","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329\u201339.","journal-title":"Lancet"},{"key":"1582_CR17","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1161\/01.CIR.98.16.1597","volume":"98","author":"ME Bertrand","year":"1998","unstructured":"Bertrand\u00a0ME, Legrand\u00a0V, Boland\u00a0J, et\u00a0al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation. 1998;98:1597\u2013603.","journal-title":"Circulation"},{"key":"1582_CR18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.ijcard.2005.03.038","volume":"108","author":"GG Biondi-Zoccai","year":"2006","unstructured":"Biondi-Zoccai\u00a0GG, Agostoni\u00a0P, Sangiorgi\u00a0GM, et al. Comparison of ticlopidine vs. clopidogrel in addition to aspirin after paclitaxel-eluting stent implantation: insights from the TRUE (Taxusin Real-life Usage Evaluation) Study. Int J Cardiol. 2006;108:406\u20137.","journal-title":"Int J Cardiol"},{"key":"1582_CR19","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","volume":"339","author":"MB Leon","year":"1998","unstructured":"Leon\u00a0MB, Baim\u00a0DS, Popma\u00a0JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N\u00a0Engl J Med. 1998;339:1665\u201371.","journal-title":"N Engl J Med"},{"key":"1582_CR20","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/j.jacc.2017.02.029","volume":"69","author":"T Palmerini","year":"2017","unstructured":"Palmerini\u00a0T, Bacchi Reggiani\u00a0L, Della Riva\u00a0D, et al. Bleeding-related deaths in relation to the duration of dual-antiplatelet therapy after coronary stenting. J\u00a0Am Coll Cardiol. 2017;69:2011\u201322.","journal-title":"J Am Coll Cardiol"},{"key":"1582_CR21","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","volume":"371","author":"L Mauri","year":"2014","unstructured":"Mauri\u00a0L, Kereiakes\u00a0DJ, Yeh\u00a0RW, et al. Twelve or 30\u00a0months of dual antiplatelet therapy after drug-eluting stents. N\u00a0Engl J Med. 2014;371:2155\u201366.","journal-title":"N Engl J Med"},{"key":"1582_CR22","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.2016.3775","volume":"315","author":"RW Yeh","year":"2016","unstructured":"Yeh\u00a0RW, Secemsky\u00a0EA, Kereiakes\u00a0DJ, et\u00a0al. Development and validation of a\u00a0prediction rule for benefit and harm of dual antiplatelet therapy beyond 1\u00a0year after percutaneous coronary intervention. JAMA. 2016;315:1735\u201349.","journal-title":"JAMA"},{"key":"1582_CR23","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","volume":"389","author":"F Costa","year":"2017","unstructured":"Costa\u00a0F, Van Klaveren\u00a0D, James\u00a0S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a\u00a0pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389:1025\u201334.","journal-title":"Lancet"},{"key":"1582_CR24","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"P Vranckx","year":"2018","unstructured":"Vranckx\u00a0P, Valgimigli\u00a0M, J\u00fcni\u00a0P, et al. Ticagrelor plus aspirin for 1\u00a0month, followed by ticagrelor monotherapy for 23\u00a0months vs aspirin plus clopidogrel or ticagrelor for 12\u00a0months, followed by aspirin monotherapy for 12\u00a0months after implantation of a\u00a0drug-eluting stent: a\u00a0multicentre, open-label, randomised superiority trial. Lancet. 2018;392:940\u20139.","journal-title":"Lancet"},{"key":"1582_CR25","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1001\/jama.2019.8146","volume":"321","author":"JY Hahn","year":"2019","unstructured":"Hahn\u00a0JY, Song\u00a0YB, Oh\u00a0JH, et\u00a0al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMARTCHOICE randomized clinical trial. JAMA. 2019;321:2428\u201337.","journal-title":"JAMA"},{"key":"1582_CR26","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1001\/jama.2019.8145","volume":"321","author":"H Watanabe","year":"2019","unstructured":"Watanabe\u00a0H, Domei\u00a0T, Morimoto\u00a0T, et al. Effect of 1\u2011month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT\u20112 randomized clinical trial. JAMA. 2019;321:2414\u201327.","journal-title":"JAMA"},{"key":"1582_CR27","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","volume":"381","author":"R Mehran","year":"2019","unstructured":"Mehran\u00a0R, Baber\u00a0U, Sharma\u00a0SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N\u00a0Engl J Med. 2019;381:2032\u201342.","journal-title":"N Engl J Med"},{"key":"1582_CR28","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1001\/jama.2020.7580","volume":"323","author":"BK Kim","year":"2020","unstructured":"Kim\u00a0BK, Hong\u00a0SJ, Cho\u00a0YH, Yun\u00a0KH, et\u00a0al. Effect of ticagrelor monotherapy vs ticagrelor with sspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020;323:2407\u201316.","journal-title":"JAMA"},{"key":"1582_CR29","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1161\/CIRCULATIONAHA.120.046251","volume":"142","author":"ML O\u2019Donoghue","year":"2020","unstructured":"O\u2019Donoghue\u00a0ML, Murphy\u00a0SA, Sabatine\u00a0MS. Safety and efficacy of aspirin discontinuation on a\u00a0background of a\u00a0P2Y 12 Inhibitor in patients after percutaneous coronary intervention: a\u00a0systematic review and meta-analysis. Circulation. 2020;142:538\u201345.","journal-title":"Circulation"},{"key":"1582_CR30","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1161\/CIRCULATIONAHA.120.046308","volume":"142","author":"SU Khan","year":"2020","unstructured":"Khan\u00a0SU, Sing\u00a0M, Valavoor\u00a0S, et al. Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents: a\u00a0systematic review and network meta-analysis. Circulation. 2020;142:1425\u201336.","journal-title":"Circulation"},{"key":"1582_CR31","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","volume":"381","author":"DMF Claassens","year":"2019","unstructured":"Claassens\u00a0DMF, Vos\u00a0GJA, Bergmeijer\u00a0TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N\u00a0Engl J Med. 2019;381:1621\u201331.","journal-title":"N Engl J Med"},{"key":"1582_CR32","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jacc.2019.11.056","volume":"75","author":"U Baber","year":"2020","unstructured":"Baber\u00a0U, Zafa\u00a0MU, Dangas\u00a0G, et\u00a0al. Ticagrelor with or without aspirin after PCI: the TWILIGHT platelet substudy. J\u00a0Am Coll Cardiol. 2020;75:578\u201386.","journal-title":"J Am Coll Cardiol"},{"key":"1582_CR33","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.jcin.2020.06.023","volume":"13","author":"N Kogame","year":"2020","unstructured":"Kogame\u00a0N, Guimaraes\u00a0PO, Modolo\u00a0R, et al. Aspirin-free prasugrel monotherapy following coronary artery stenting in patients with stable CAD: the ASET pilot study. JACC Cardiovasc Interv. 2020;13:2251\u201362.","journal-title":"JACC Cardiovasc Interv"},{"key":"1582_CR34","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1161\/CIRCULATIONAHA.120.050645","volume":"142","author":"K Szummer","year":"2020","unstructured":"Szummer\u00a0K, Montez-Rath\u00a0ME, Alfredsson\u00a0J, et al. Comparison between ticagrelor and clopidogrel in elderly patients with an acute coronary syndrome: insights from the SWEDEHEART registry. Circulation. 2020;142:1700\u20138.","journal-title":"Circulation"},{"key":"1582_CR35","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.4244\/EIJ-D-17-00634","volume":"13","author":"P Zocca","year":"2017","unstructured":"Zocca\u00a0P, Van der Heijden\u00a0LC, Kok\u00a0MM, et al. Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT. EuroIntervention. 2017;13:1168\u201376.","journal-title":"EuroIntervention"},{"key":"1582_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ahj.2016.12.001","volume":"185","author":"H Lee","year":"2017","unstructured":"Lee\u00a0H, Bon-Kwon\u00a0K, Park\u00a0KW, et al. A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy (HOST-EXAM) trial. Am Heart\u00a0J. 2017;185:17\u201325.","journal-title":"Am Heart J"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-021-01582-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-021-01582-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-021-01582-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T09:51:19Z","timestamp":1635501079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-021-01582-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1582"],"URL":"https:\/\/doi.org\/10.1007\/s12471-021-01582-7","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,8]]},"assertion":[{"value":"3 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.W.A.\u00a0Verheugt has received honoraria for consulting and presentations from AstraZeneca, Bayer Healthcare and Daiichi-Sankyo. P.\u00a0Damman has received consultancy fees from Philips and Abbott, and research grants from Philips, Abbott and AstraZeneca. R.-J.M.\u00a0van Geuns reports personal fees from Abbott vascular, grants and personal fees from AstraZeneca, grants and personal fees from Amgen, grants and personal fees from Boston Scientific, and personal fees from Sanofi. S.A.J.\u00a0Damen, J.J.\u00a0Wykrzykowska and E.C.I.\u00a0Woelders declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}